NO324902B1 - Fremgangsmate ved utvinning av faktor VIII/vWF-kompleks ved hjelp av kationebytterkromatografi, faktor VIII/vWF-kompleks saledes fremstilt, samt preparat inneholdende samme og anvendelse derav - Google Patents
Fremgangsmate ved utvinning av faktor VIII/vWF-kompleks ved hjelp av kationebytterkromatografi, faktor VIII/vWF-kompleks saledes fremstilt, samt preparat inneholdende samme og anvendelse derav Download PDFInfo
- Publication number
- NO324902B1 NO324902B1 NO19994137A NO994137A NO324902B1 NO 324902 B1 NO324902 B1 NO 324902B1 NO 19994137 A NO19994137 A NO 19994137A NO 994137 A NO994137 A NO 994137A NO 324902 B1 NO324902 B1 NO 324902B1
- Authority
- NO
- Norway
- Prior art keywords
- vwf
- complex
- factor
- factor viii
- vwf complex
- Prior art date
Links
- 108010054218 Factor VIII Proteins 0.000 title claims description 84
- 102000001690 Factor VIII Human genes 0.000 title claims description 84
- 229960000301 factor viii Drugs 0.000 title claims description 84
- 238000000034 method Methods 0.000 title claims description 41
- 238000002360 preparation method Methods 0.000 title claims description 30
- 238000005277 cation exchange chromatography Methods 0.000 title claims description 24
- 238000011084 recovery Methods 0.000 title description 7
- 108010047303 von Willebrand Factor Proteins 0.000 claims description 182
- 230000000694 effects Effects 0.000 claims description 49
- 150000001768 cations Chemical class 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 238000010828 elution Methods 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 208000009292 Hemophilia A Diseases 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 7
- 238000003776 cleavage reaction Methods 0.000 claims description 6
- 230000007017 scission Effects 0.000 claims description 6
- 208000031220 Hemophilia Diseases 0.000 claims description 5
- 201000003542 Factor VIII deficiency Diseases 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 230000002458 infectious effect Effects 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000012460 protein solution Substances 0.000 claims description 4
- 239000007853 buffer solution Substances 0.000 claims description 3
- 238000004113 cell culture Methods 0.000 claims description 3
- 238000005194 fractionation Methods 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- -1 sulfopropyl Chemical group 0.000 claims description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 230000004523 agglutinating effect Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 61
- 239000011780 sodium chloride Substances 0.000 description 31
- 238000000746 purification Methods 0.000 description 29
- 102100026735 Coagulation factor VIII Human genes 0.000 description 24
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 24
- 239000000872 buffer Substances 0.000 description 17
- 150000001450 anions Chemical class 0.000 description 11
- 238000005341 cation exchange Methods 0.000 description 11
- 241000700605 Viruses Species 0.000 description 7
- 238000005571 anion exchange chromatography Methods 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 238000001179 sorption measurement Methods 0.000 description 6
- 238000001042 affinity chromatography Methods 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 229960002897 heparin Drugs 0.000 description 5
- 229920000669 heparin Polymers 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000011097 chromatography purification Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229910001679 gibbsite Inorganic materials 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 102000023159 Platelet Glycoprotein GPIb-IX Complex Human genes 0.000 description 1
- 108010045766 Platelet Glycoprotein GPIb-IX Complex Proteins 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 244000000009 viral human pathogen Species 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0033897A AT406373B (de) | 1997-02-27 | 1997-02-27 | Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie |
| PCT/AT1998/000043 WO1998038220A1 (de) | 1997-02-27 | 1998-02-27 | Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO994137D0 NO994137D0 (no) | 1999-08-26 |
| NO994137L NO994137L (no) | 1999-08-26 |
| NO324902B1 true NO324902B1 (no) | 2007-12-27 |
Family
ID=3487946
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19994137A NO324902B1 (no) | 1997-02-27 | 1999-08-26 | Fremgangsmate ved utvinning av faktor VIII/vWF-kompleks ved hjelp av kationebytterkromatografi, faktor VIII/vWF-kompleks saledes fremstilt, samt preparat inneholdende samme og anvendelse derav |
| NO20071357A NO326257B1 (no) | 1997-02-27 | 2007-03-13 | "Fremgangsmate ved utvinning av faktor VIII:C" |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20071357A NO326257B1 (no) | 1997-02-27 | 2007-03-13 | "Fremgangsmate ved utvinning av faktor VIII:C" |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US6831159B1 (enExample) |
| EP (1) | EP0971958B2 (enExample) |
| JP (1) | JP4250771B2 (enExample) |
| AR (2) | AR010121A1 (enExample) |
| AT (2) | AT406373B (enExample) |
| AU (1) | AU744919B2 (enExample) |
| CA (1) | CA2282841C (enExample) |
| DE (1) | DE59814211D1 (enExample) |
| ES (1) | ES2306471T5 (enExample) |
| NO (2) | NO324902B1 (enExample) |
| WO (1) | WO1998038220A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT406373B (de) | 1997-02-27 | 2000-04-25 | Immuno Ag | Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie |
| EP1593388A1 (en) * | 2004-05-05 | 2005-11-09 | ZLB Behring GmbH | Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers |
| US11197916B2 (en) | 2007-12-28 | 2021-12-14 | Takeda Pharmaceutical Company Limited | Lyophilized recombinant VWF formulations |
| ES2298096B1 (es) | 2008-01-08 | 2009-01-01 | Grifols, S.A. | Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos. |
| HRP20130414T1 (en) | 2008-10-21 | 2013-06-30 | Baxter International Inc. | Lyophilized recombinant vwf formulations |
| HUE026907T2 (en) * | 2009-08-20 | 2016-07-28 | Baxalta Inc | Clean VWF to enhance removal of non-lipid enveloped viruses |
| RU2579977C2 (ru) | 2009-11-13 | 2016-04-10 | Грифольс Терапьютикс Инк. | СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ |
| KR101997543B1 (ko) | 2010-07-30 | 2019-07-09 | 이엠디 밀리포어 코포레이션 | 크로마토그래피 매질 및 방법 |
| AU2011343813B2 (en) | 2010-12-15 | 2015-05-21 | Takeda Pharmaceutical Company Limited | Eluate collection using conductivity gradient |
| DK3412305T3 (da) * | 2011-06-10 | 2021-03-01 | Baxalta GmbH | Behandling af koagulationssygdom ved administration af rekombinant vwf |
| HRP20171272T4 (hr) | 2011-08-02 | 2020-08-07 | Baxalta GmbH | Sustavi i metode za povećanje prinosa proteina iz postupka rekombinatne proizvodnje |
| NZ631702A (en) | 2012-06-15 | 2017-01-27 | Grains Res & Dev Corp | Production of long chain polyunsaturated fatty acids in plant cells |
| US20150315263A1 (en) * | 2012-11-30 | 2015-11-05 | Centre For Bioseparation Technology - Vit | Monolith-based pseudo-bioaffinity purification methods for factor viii and applications thereof |
| DK3066119T3 (en) * | 2013-11-08 | 2018-11-12 | Csl Ltd | NEW PROCEDURE FOR CONCENTRATION OF THE VON WILLEBRAND FACTOR OR COMPLEXES OF IT |
| EP3082405A4 (en) | 2013-12-18 | 2017-12-13 | Commonwealth Scientific and Industrial Research Organisation | Lipid comprising long chain polyunsaturated fatty acids |
| PH12016502586B1 (en) | 2014-06-27 | 2023-07-19 | Commw Scient Ind Res Org | Lipid comprising docosapentaenoic acid |
| EP3188816B1 (en) | 2014-09-02 | 2021-06-09 | EMD Millipore Corporation | Chromatography media comprising discrete porous bundles of nanofibrils |
| CA2966515C (en) | 2014-12-08 | 2021-04-27 | Emd Millipore Corporation | Mixed bed ion exchange adsorber |
| JP7307047B2 (ja) | 2017-07-07 | 2023-07-11 | 武田薬品工業株式会社 | 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療 |
| JP2022524291A (ja) | 2019-02-01 | 2022-05-02 | 武田薬品工業株式会社 | 組換えＶＷＦ（ｒＶＷＦ）を使用する予防治療法 |
| CN114106145B (zh) * | 2021-10-22 | 2023-09-01 | 山东泰邦生物制品有限公司 | 一种血源人凝血因子ⅷ/血管性血友病因子复合物生产工艺 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4540573A (en) | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
| GB8403473D0 (en) * | 1984-02-09 | 1984-03-14 | Special Trustees For St Thomas | Purification of factor viii |
| US5200510A (en) * | 1987-06-16 | 1993-04-06 | Zymogenetics, Inc. | Method for purifying factor viii:c, von willebrand factor and complexes thereof |
| FR2651437A1 (fr) | 1989-09-05 | 1991-03-08 | Lille Transfusion Sanguine | Procede de preparation de concentre du complexe facteur viii-facteur von willebrand de la coagulation sanguine a partir de plasma total. |
| NZ237244A (en) * | 1990-03-02 | 1992-10-28 | Bio Technology General Corp | Cloning and production of human von willebrand factor analogues and compositions thereof |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| IT1256622B (it) † | 1992-12-04 | 1995-12-12 | Sclavo Spa | Processo per l'estrazione del complesso fattore viii-fattore von willebrand (fviii:c-fvw) da plasma umano totale. |
| AT401270B (de) | 1994-09-26 | 1996-07-25 | Immuno Ag | Verfahren zur quantifizierung von genomischer dna |
| CA2159044A1 (en) * | 1994-09-26 | 1996-03-27 | Falko-Guenter Falkner | Method of quantitating nucleic acids |
| DE4435392B4 (de) * | 1994-10-04 | 2008-02-07 | Immuno Ag | Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF |
| DE4435485C1 (de) * | 1994-10-04 | 1996-03-21 | Immuno Ag | Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor |
| AT403764B (de) | 1996-03-15 | 1998-05-25 | Immuno Ag | Stabiler faktor viii/vwf-komplex |
| CA2251558C (en) | 1996-04-12 | 2005-11-22 | Immuno Aktiengesellschaft | Highly purified factor viii complex |
| AT403765B (de) | 1996-04-12 | 1998-05-25 | Immuno Ag | Verfahren zur herstellung einer präparation enthaltend einen hochgereinigten komplex |
| AT406373B (de) | 1997-02-27 | 2000-04-25 | Immuno Ag | Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie |
| AT405403B (de) | 1997-02-27 | 1999-08-25 | Immuno Ag | Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie |
-
1997
- 1997-02-27 AT AT0033897A patent/AT406373B/de not_active IP Right Cessation
-
1998
- 1998-02-25 AR ARP980100835A patent/AR010121A1/es active IP Right Grant
- 1998-02-27 AT AT98905132T patent/ATE391728T1/de active
- 1998-02-27 AU AU60806/98A patent/AU744919B2/en not_active Expired
- 1998-02-27 CA CA002282841A patent/CA2282841C/en not_active Expired - Lifetime
- 1998-02-27 DE DE59814211T patent/DE59814211D1/de not_active Expired - Lifetime
- 1998-02-27 ES ES98905132T patent/ES2306471T5/es not_active Expired - Lifetime
- 1998-02-27 WO PCT/AT1998/000043 patent/WO1998038220A1/de not_active Ceased
- 1998-02-27 US US09/367,459 patent/US6831159B1/en not_active Expired - Lifetime
- 1998-02-27 JP JP53706098A patent/JP4250771B2/ja not_active Expired - Lifetime
- 1998-02-27 EP EP98905132A patent/EP0971958B2/de not_active Expired - Lifetime
-
1999
- 1999-08-26 NO NO19994137A patent/NO324902B1/no not_active IP Right Cessation
-
2001
- 2001-11-02 US US10/003,621 patent/US6953837B2/en not_active Expired - Lifetime
-
2004
- 2004-02-27 US US10/789,562 patent/US7648958B2/en not_active Expired - Fee Related
-
2007
- 2007-03-13 NO NO20071357A patent/NO326257B1/no not_active IP Right Cessation
- 2007-03-15 AR ARP070101059A patent/AR059902A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2306471T5 (es) | 2012-06-07 |
| ES2306471T3 (es) | 2008-11-01 |
| NO994137D0 (no) | 1999-08-26 |
| NO20071357L (no) | 1999-08-26 |
| US6831159B1 (en) | 2004-12-14 |
| AU6080698A (en) | 1998-09-18 |
| NO326257B1 (no) | 2008-10-27 |
| AU744919B2 (en) | 2002-03-07 |
| CA2282841A1 (en) | 1998-09-03 |
| EP0971958A1 (de) | 2000-01-19 |
| JP4250771B2 (ja) | 2009-04-08 |
| US20050239171A1 (en) | 2005-10-27 |
| US20020058625A1 (en) | 2002-05-16 |
| EP0971958B2 (de) | 2012-02-08 |
| DE59814211D1 (de) | 2008-05-21 |
| NO994137L (no) | 1999-08-26 |
| WO1998038220A1 (de) | 1998-09-03 |
| US7648958B2 (en) | 2010-01-19 |
| ATE391728T1 (de) | 2008-04-15 |
| CA2282841C (en) | 2008-12-02 |
| EP0971958B1 (de) | 2008-04-09 |
| US6953837B2 (en) | 2005-10-11 |
| AR010121A1 (es) | 2000-05-17 |
| AT406373B (de) | 2000-04-25 |
| ATA33897A (de) | 1999-09-15 |
| JP2001517212A (ja) | 2001-10-02 |
| AR059902A2 (es) | 2008-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO326257B1 (no) | "Fremgangsmate ved utvinning av faktor VIII:C" | |
| JP3435668B2 (ja) | 高純度で治療用に適した標準化ヒト フオン・ビルブラント因子濃厚液の工業規模製造の方法 | |
| JP3701028B2 (ja) | 高純度フォンビルブラント因子の入手方法 | |
| US4877608A (en) | Pharmaceutical plasma protein formulations in low ionic strength media | |
| NO324659B1 (no) | Utvinning av von Willebrand-faktor ved kationebytterkromatografi samt preparat inneholdende slik faktor og anvendelse derav. | |
| CA2645701C (en) | Process for obtaining a concentrate of von willebrand factor or a complex of factor viii/von willebrand factor and use of the same | |
| RU2603103C2 (ru) | Способ получения фибриногена с использованием сильной анионообменной смолы и содержащий фибриноген продукт | |
| JP2000506869A (ja) | 安定な因子ｖｉｉｉ／▲下ｖ▼ｗｆ複合体 | |
| AU2003244850B2 (en) | Processes for the preparation of fibrinogen | |
| NO167627B (no) | Fremgangsmaate for rensing av faktor viii:c. | |
| DK174066B1 (da) | Fremgangsmåde til fremstilling af et faktor VIII-præparat | |
| MXPA02010017A (es) | Preparacion activa hemostaticamente, que contiene el factor de von willebrand y metodo para la produccion de la misma. | |
| JP2004123744A (ja) | Ｖｉｉｉ因子：ｃ含有フォンビルブラント因子の濃縮物およびそれに関連する方法 | |
| EP0052874A1 (en) | Method for synthesizing procoagulant factor VIII activity | |
| US11608358B2 (en) | Method of preparing composition containing factor VIII (FVIII) and von Willebrand factor (vWF) with controlled content of von Willebrand factor (vWF) | |
| Foster et al. | Studies on the Stability of VIII: C during the Manufacture of a Factor VIII Concentrate for Clinical Use 1 | |
| Sibinga | Factor VIII in Regional Blood Banking Practice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: BAXALTA INCORPORATED, CH |
|
| MK1K | Patent expired |